Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GNKG168 |
| Synonyms | |
| Therapy Description |
GNKG168 is a synthetic oligodeoxynucleotide that binds to and activates TLR9, which may lead to downstream signaling of various pathways, potentially stimulating innate immunity, and inducing cytotoxic T-lymphocytes and antibody-dependent cellular cytotoxicity (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GNKG168 | GNKG 168|CpG ODN GNKG-168 | TLR9 Agonist 9 | GNKG168 is a synthetic oligodeoxynucleotide that binds to and activates TLR9, which may lead to downstream signaling of various pathways, potentially stimulating innate immunity, and inducing cytotoxic T-lymphocytes and antibody-dependent cellular cytotoxicity (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|